Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin and exenatide effects on appetite-related brain circuits in obese adults with type 2 diabetes
NL-OMON48777Phase 4Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Aug 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dapagliflozin and exenatide in type 2 diabetes mellitus (T2DM) and obesity (4 arms), sponsored by Vrije University Medical Center. Primary endpoint: Food cue-related neuronal activity in central reward and satiety circuits at 16 weeks. Started Aug 2017; status: active, not recruiting.
02
Drugs
dapagliflozinexenatide
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NL-OMON48777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48777.